AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (238.9 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Immunology and immunotherapy in breast cancer

Vladimir Semiglazov( ), Andrey Tseluiko, Asel Kudaybergenova, Anna Artemyeva, Petr Krivorotko, Roman Donskih
Petrov National Medicine Cancer-Research Center Ministry of Health, Saint-Petersburg 197758, Russia
Show Author Information

Abstract

Immuno-oncology is a rapidly developing field in medicine. Drug combination therapies have already been studied in many clinical trials on various tumor types. In recent years, a checkpoint inhibition therapy with monoclonal antibodies targeting PD-1 and its ligand PD-L1 has been developed. Breast cancer had been examined in the field of immune-oncology relatively recently. This review focuses on clinical evidence regarding immune checkpoint inhibition for curative treatment of various breast cancer subtypes. In addition, we present the results of studies demonstrating the prognostic and predictive value of levels of tumor-infiltrating lymphocytes (CD4 and CD8), their quantitative ratios, and their correlation with regulatory genes (PD-1, PD-L1, and FOX-P3).

Keywords

immunotherapyBreast cancertumor-infiltrating lymphocytesPD-1PD-L1

References

1

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3: 991-8.
Crossref Google Scholar
2

Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011; 331: 1565-70.
Crossref Google Scholar
3

Franzoi MA, Romano E, Piccart M. Immunotherapy for early breast cancer: too soon, too superficial, or just right? Ann Oncol. 2021; 32: 323-6.
Crossref Google Scholar
4

Sobral-Leite M, van de Vijver K, Michaut M, van der Linden R, Hooijer GKJ, Horlings HM et al. Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival. Oncoimmunology. 2018; 7: e1509820.
Crossref Google Scholar
5

Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2016; 2: 1354-60.
Crossref Google Scholar
6
Tseluiko A, Semiglazov V, Kudaibergenova A, Urezkova M, Artemieva A, Krivorotko P. The role of tumor-infiltrating lymphocytes, prognostic and predictive signification in breast cancer. In: 17th St. Gallen International Breast Cancer Conference/The Breast 56S1; 2021: P118, S65.
Crossref
7

Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019; 20: e175-86.
Crossref Google Scholar
8

Cimino-Mathews A, Thompson E, Taube JM, Ye X, Lu Y, Meeker A, et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol. 2016; 47: 52-63.
Crossref Google Scholar
9
Emens L, Nanda R. Breast cancer immunotherapy. In: Butterfield L, Kaufman H, Marincola F, Sectrion Ⅳ, Ascieto P, editors. Cancer immunotherapy. Principal and practice. 2017, 702-16[chapter 46].
10

Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016; 13: 228-41.
Crossref Google Scholar
11

Loi S, Michiels S, Loibl S, Budczies J, Denkert C, Adams S, et al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann Oncol. 2021; 32: 1236-44.
Crossref Google Scholar
12

Park JH, Jonas SF, Bataillon G, Criscitiello C, Salgado R, Loi S, et al. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Ann Oncol. 2019; 30: 1941-49.
Crossref Google Scholar
13

De Jong VMT, Wang Y, Opdam M, ter Hoeve N, Jóźwiak K, Hauptmann M, et al. Prognostic value of tumour-infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group. Ann Oncol. 2020; 31: S303-39.
Crossref Google Scholar
14

Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol. 2015; 1: 448-54.
Crossref Google Scholar
15

Ali HR, Provenzano E, Dawson S-J, Blows FM, Liu B, Shah M, et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014; 25: 1536-43.
Crossref Google Scholar
16

Dieci MV, Mathieu MC, Guarneri V, Conte P, Delaloge S, Andre F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase Ⅲ randomized adjuvant breast cancer trials. Ann Oncol. 2015; 26: 1698-704.
Crossref Google Scholar
17

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014; 25: 1544-50.
Crossref Google Scholar
18

Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, et al. Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer. JAMA Oncol. 2016; 2: 56-64.
Crossref Google Scholar
19

Denkert C, Von Minckwitz G, Brase JC, Sinn BV, Gade G, Kronenwett R, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015; 33: 983-91.
Crossref Google Scholar
20

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384: 164-72.
Crossref Google Scholar
21
Urezkova M, Kudaybergenova A, Semiglazova T, Semiglazov V, Tseluiko A, Artemyeva A, et al. TILs in triple –positive breast cancer. In: 17th St Gallen breast cancer conference, 2021, Poster Abstract/The Breast 56S1(2021), P027, S17-90.
Crossref
22

Disis ML, Stanton SE. Triple negative breast cancer: immune modulation as the new treatment paradigm. Am Soc Clin Oncol Educ Book. 2015; 35: e25-30.
Crossref Google Scholar
23

Stephens PJ, Tarpey PS, Davies H, Loo PV, Greenman C, Wedge DC, et al. Oslo Breast Cancer Consortium (OSBREAC). The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486: 400-4.
Crossref Google Scholar
24

Smid M, Hoes M, Sieuwerts AM, Sleijfer S, Zhang Y, Wang Y, et al. Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. Breast Cancer Res Treat. 2011; 128: 23-30.
Crossref Google Scholar
25

Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490: 61-70.
Crossref Google Scholar
26

Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012; 486: 405-9.
Crossref Google Scholar
27

Creighton CJ. The molecular profile of luminal B breast cancer. Biologics. 2012; 6: 289-97.
Crossref Google Scholar
28

Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 2015; 121: 8-16.
Crossref Google Scholar
29

Petersen J, Wurzbacher SJ, Williamson NA, Ramarathinam SH, Reid HH, Nair AK, et al. Phosphorylated self-peptides alter human leukocyte antigen class Ⅰ-restricted antigen presentation and generate tumor-specific epitopes. Proc Natl Acad Sci U S A. 2009; 106: 2776-81.
Crossref Google Scholar
30

Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res. 2011; 13: R97.
Crossref Google Scholar
31

Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010; 28: 105-13.
Crossref Google Scholar
32

Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012; 14: R48.
Crossref Google Scholar
33

Müller P, Kreuzaler M, Khan T, Thommen DS, Martin K, Glatz K, et al. Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Transl Med. 2015; 7: 315ra188.
Crossref Google Scholar
34

Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006; 24: 5373-80.
Crossref Google Scholar
35

Liu S, Foulkes WD, Leung S, Gao D, Lau S, Kos Z, et al. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res. 2014; 16: 432.
Crossref Google Scholar
36

Lu L, Cantor H. Generation and regulation of CD8(+) regulatory T cells. Cell Mol Immunol. 2008; 5: 401-6.
Crossref Google Scholar
37

Liu F, Lang R, Zhao J, Zhang X, Pringle GA, Fan Y, et al. CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. 2011; 130: 645-55.
Crossref Google Scholar
38

Tolaney SM, Barroso-Sousa R, Keenan T, Li T, Trippa L, Vaz-Luis I, et al. Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor–positive, ERBB2-Negative Metastatic Breast Cancer: a randomized clinical trial[Internet]. JAMA Oncol. 2020; 6: 1355-62.
Crossref Google Scholar
39
I-SPY2 Trial Consortium: Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, et al. Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial. JAMA Oncol. 2020, 6: 1355-62.
40

Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020; 6: 676-84.
Crossref Google Scholar
41
Liu MC, Robinson PA, Yau C, Wallace AM, Chien A, Stringer-Reasor E, et al. Evaluation of a pembrolizumab-8 cycle neoadjuvant regimen without AC for high-risk early-stage HER2-negative breast cancer: results from the I-SPY 2 TRIAL. Presented at the 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas. Abstract P3-09-02.
42

Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, et al. Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nat Commun. 2020; 11: 3584.
Crossref Google Scholar
43

Liu F, Li Y, Ren M, Zhang X, Guo X, Lang R, et al. Peritumoral FOXP3+ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3+ regulatory T cell is prognostic predictor of breast cancer patients. Breast Cancer Res Treatment. 2012; 135: 459-67.
Crossref Google Scholar
44

Miyashita M, Sasano H, Tamaki K, Hirakawa H, Takahashi Y, Nakagawa S, et al. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res. 2015; 17: 124.
Crossref Google Scholar
45

Mahmoud SMA, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AHS, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011; 29: 1949-55.
Crossref Google Scholar
46

Mahmoud SMA, Paish EC, Powe DG, Macmillan RD, Lee AH, Ellis IO, et al. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat. 2011; 127: 99-108.
Crossref Google Scholar
47

Oda N, Shimazu K, Naoi Y, Morimoto K, Shimomura A, Shimoda M, et al. Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients. Breast Cancer Res Treat. 2012; 136: 107-16.
Crossref Google Scholar
48

West NR, Kost SE, Martin SD, Milne K, Deleeuw RJ, Nelson BH, et al. Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor negative breast cancer. Br J Cancer. 2013; 108: 155-62.
Crossref Google Scholar
49

Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, et al. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res. 2013; 19: 28-33.
Crossref Google Scholar
50

Luen S, Virassamy B, Savas P, Salgado R, Loi S. The genomic landscape of breast cancer and its interaction with host immunity. Breast. 2016; 29: 241-50.
Crossref Google Scholar
51

Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018; 19: 40-50.
Crossref Google Scholar
52

Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019; 37: 559-69.
Crossref Google Scholar
53

Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014; 2: 361.
Crossref Google Scholar
54

Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015; 6: 5449-64.
Crossref Google Scholar
55

Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015; 28: 690-714.
Crossref Google Scholar
56

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018; 379: 2108-21.
Crossref Google Scholar
57

Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44-59.
Crossref Google Scholar
58

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019; 25: 920-8.
Crossref Google Scholar
59

Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021; 32: 983-93.
Crossref Google Scholar
60

Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase Ⅲ trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021; 32: 994-1004.
Crossref Google Scholar
61

Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020; 396: 1817-28.
Crossref Google Scholar
62

Voorwerk L, Kok M. ‘IMpassionate conflicts’ in immunotherapy trials for metastatic triple-negative breast cancer. Ann Oncol. 2021; 32: 947-9.
Crossref Google Scholar
63

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020; 382: 810-21.
Crossref Google Scholar
64

Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017; 17: 233-47.
Crossref Google Scholar
65

Petrelli F, Signorelli D, Ghidini M, Ghidini A, Pizzutilo EG, Ruggieri L, et al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers (Basel). 2020; 12: 546.
Crossref Google Scholar
66

Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008; 8: 59-73.
Crossref Google Scholar
67

Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw. 2020; 18: 479-89.
Crossref Google Scholar
68

Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020; 396: 1090-100.
Crossref Google Scholar
69
Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. In: Presented at the 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019, San Antonio, Texas. Abstract GS3-04. 37.
Crossref
70

Gianni L, Huang C-S, Egle D, Bermejo B, Zamagni C, Thill M, et al. Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. Cancer Res. 2020; 80: GS3-04.
Crossref Google Scholar
71

Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, et al. A randomised phase Ⅱ study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019; 30: 1279-88.
Crossref Google Scholar
72

Loibl S, Schneeweiss A, Huober JB, Braun M, Rey J, Blohmer JU, et al. Durvalumab improves long-term outcome in TNBC: results from the phase Ⅱ randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). J Clin Oncol. 2021; 39: 506.
Crossref Google Scholar
73

Bianchini G, Huang C, Egle D, Bermejo B, Zamagni C, Yhill M, et al. LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial. Ann Oncol. 2020; 31: S1142-215.
Crossref Google Scholar
74

Semiglazov VF, Tseluiko AI, Baldueva IA, Nekhaeva TL, Artemyeva AS, Kudaybergenova AG, et al. Immunology and immunotherapy in the complex treatment of malignant tumors. Meditsinskiy sovet = Medical Council. 2021; 248-257 (in Russian).
Crossref Google Scholar
75

Zhang Y, Wang S, Yang B, Lu S, Du Y, Liu H. Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients. Cancer Biol Med. 2019; 16: 350-60.
Crossref Google Scholar
76

Loriot Y, Marabelle A, Guégan JP, Danlos FX, Besse B, Chaput N, et al. Plasma proteomics identifies Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. Ann Oncol. 2021; 32: S1381-90.
Crossref Google Scholar
Cancer Biology & Medicine
Volume 19 Issue 5,
May 2022
Pages 609-618
DOI: 10.20892/j.issn.2095-3941.2021.0597
Cite this article:
Semiglazov V, Tseluiko A, Kudaybergenova A, et al. Immunology and immunotherapy in breast cancer. Cancer Biology & Medicine, 2022, 19(5): 609-618. https://doi.org/10.20892/j.issn.2095-3941.2021.0597

210

Views

3

Downloads

13

Crossref

15

Web of Science

14

Scopus

Altmetrics
Received: 16 December 2021
Accepted: 07 March 2022
Published: 24 June 2022
©2022 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License
Return